Lilly to sell obesity drugs directly on Hims & Hers site
LLY•Eli Lilly struck a deal allowing Hims & Hers to sell Zepbound and Foundayo directly on its platform. Self-pay prices start at $149 per month for Foundayo and $299 for Zepbound.
1. Direct platform sales
Eli Lilly said Hims & Hers will sell its obesity drugs Zepbound and Foundayo directly on the telehealth company’s platform. Previously, patients had to leave the site and use LillyDirect to access the drugs.
2. Pricing and terms
Self-pay prices start at $149 per month for Foundayo and $299 for Zepbound, matching prices on LillyDirect. Lilly USA President Ilya Yuffa said Hims & Hers agreed not to sell compounded versions or knockoffs of Lilly’s obesity medications.
3. Market context
The deal follows Hims & Hers’ agreement to sell Novo Nordisk’s Wegovy and Ozempic on its platform. Lilly said 40% to 45% of Zepbound sales are through self-pay channels; analysts have said Hims & Hers may benefit next year if employers drop coverage of weight-loss drugs.
